<DOC>
	<DOCNO>NCT00778154</DOCNO>
	<brief_summary>Patients receive appropriate number year alendronate risedronate therapy recruit . Each patient receive baseline BMD measurement perform spine hip DXA . Each patient receive tetracycline label bone transiliac bone biopsy . One year later teh bone label biopsy procedure repeat .</brief_summary>
	<brief_title>Study Bone Histomorphometry , Microarchitecture , Matrix Structure Patients Receiving Alendronate Risedronate</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Women least 5 year postmenopausal Subjects treat combination alendronate 10 mg daily 70 mg weekly combination risedronate 5mg daily 35 mg weekly 35 year . Or subject treat combination alendronate 10 mg daily 70 mg weekly combination risedronate 5mg daily 35 mg weekly great 5 year . Presence metabolic bone disease PMO Use medication alendronate risedronate within past 6 month likely interfere skeletal homeostasis . Uncontrolled hyperthyroidism . Previous history malignancy except treat squamous cell basal cell carcinoma skin . Alcohol drug abuse , current within past 5 year . Allergy tetracycline , Novocain , Versed . Hip anatomy conducive transiliac bone biopsy DXA scan . Previous bilateral transiliac bone biopsy .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>